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E
xtensive and informative immunological assess-
ments of islet transplant recipients have been
limited due, in part, to the smaller numbers of
patients transplanted compared with solid or-
gan trials. Limitations related to blood volume and the
logistical challenges of collecting multiple posttransplant
samples for drug levels as well as clinical and metabolic
parameters also pose challenges. Several variables affect
islet allograft outcome, including allo- and autoimmune
responses to transplanted islets, -cell mass and islet
quality, efﬁcacy of the immunosuppressive regimen and its
effect on islet function, as well as glycemic control. In fact,
much debate has centered on whether or not islet attrition
is due to immune-mediated loss, death of overworked
cells caused by insufﬁcient mass, and/or diabetogenic
effect of various immune intervention agents. In addi-
tion, many of these parameters may have differing
effects based on the transplanted mass, with marginal
mass transplants being more susceptible to immune-
mediated or stress-induced loss.
Recently, several studies have demonstrated immuno-
logical alterations in islet allograft patients. Posttransplant
changes in lymphocytes and lymphocyte subsets were
reported to be variable depending on the immune suppres-
sion used but have not yet been associated with graft
status or speciﬁc clinical outcomes (1–4). Higher post-
transplant cytotoxic T-cell precursor frequency against
donor antigens was associated with poorer outcome at 6
months in recipients treated with sirolimus-based mainte-
nance therapy but not tacrolimus–mycophenolate mofetil
(5). In one study, cytokine production in allogeneic mixed
lymphocyte reactions (MLRs) was skewed toward a Th2
proﬁle in recipients who achieved insulin independence,
but no differences were noted between groups prior to
transplant (6). Hyporesponsive posttransplant MLRs have
been observed in islet recipients treated with steroid-free
immune suppression (3) and in islet/stem cell recipients
(2), with increases above baseline occurring subsequent to
graft rejection. All of these ﬁndings are associated with
eventual graft outcome, as opposed to demonstration of
predictive changes in the posttransplant period, and pro-
vide indications to the immunological alterations that have
occurred in successfully transplanted recipients. Elevation
of cytotoxic lymphocyte gene expression has been shown
to predict impending islet allograft rejection in nonhuman
primates (7) and clinical islet transplant recipients (2,3,8).
Alloantibodies are generally not observed until a patient
has already lost signiﬁcant islet function and immune
suppression is being tapered or has been discontinued
(3,9), and autoantibody status has not been proven to
impact islet allograft outcome (2,3,10). In the absence of a
clinical assay that is associated with rejection, such as
creatinine for renal and amylase for pancreatic allografts,
the lack of a validated marker of islet rejection remains a
challenge to be overcome and limits the ability to interfere
at an early stage of graft loss.
In this issue of Diabetes, Hilbrands et al. (4) demon-
strate that higher baseline total and B lymphocyte cell
counts, as well as T-cell autoreactivity to islet antigens, are
associated with poorer islet transplant outcome. The anal-
yses of immune and graft outcome parameters included 30
nonuremic, C-peptide–negative type 1 diabetic patients
who received an intraportal islet cell graft under the cover
of anti-thymocyte globulin induction and maintenance
with tacrolimus and mycophenolate mofetil. Absolute leu-
kocyte, lymphocyte, and lymphocyte subset (T-, B-, and
natural killer cell) counts, autoantibodies, and T-cell auto-
reactivity were compared with achievement of insulin
independence, plasma C-peptide, and glycemic variability
at 6 months posttransplant. Fifteen patients were insulin
independent at 6 months and were compared with those
who were not. Observed correlations from univariate
analysis were further examined in a multivariate model. At
baseline, patients who would ultimately become insulin
independent had signiﬁcantly lower total lymphocyte, as
well as CD19 B- and CD3 T-cell counts, with a lower
count of CD3/8 T-cells contributing to the difference in
CD3 cells. There was no association between baseline
autoantibody positivity and graft outcome. However, T-
cell autoreactivity against IA-2 and/or GAD was lower at
baseline in the group that became insulin independent;
this effect was speciﬁc for recipients of suboptimal -cell
mass (4,11). The authors conclude that prospective studies
are needed to assess whether control of these character-
istics can help increase the function of islet cell grafts
during the ﬁrst posttransplant year.
As previously mentioned, the logistics of posttransplant
sample collection are challenging, and the blood volume
required for many assays necessitates that relatively few
samples are collected over time, with quarterly monitoring
being fairly standard. This background, together with
the constantly changing immunosuppressive landscape,
makes it difﬁcult to convincingly demonstrate the utility/
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outcome. The results in the article by Hilbrands et al. offer
potentially very useful and logistically simple assessments
that can be done prior to transplant to determine which
patients are most likely to become insulin independent.
The studies can be done while the patient is on the
waiting list and can be relatively easily scheduled for a
blood draw. Analyses of total lymphocyte as well as
CD3/8 T- and B-cell counts in addition to T-cell–directed
autoreactivity to IA-2 and GAD could provide a useful
tool for tailoring transplant strategy. As an example, if
the -cell mass available for transplant is low, one
would not want to transplant a patient with baseline
T-cell autoreactivity. It will be of interest to undertake
similar analyses for islet transplant patients being
treated with immune intervention protocols that are not
thymoglobulin–mycophenolate mofetil based. If base-
line assessment of cell counts and T-cell autoreactivity
can predict outcome, as suggested by the results and
schematically represented in Fig. 1, it would be impor-
tant to add an additional immune intervention agent for
patients who have higher baseline immune parameters.
Agents that target -cells and memory T-cell popula-
tions are good candidates for additional therapeutics, as
are blockers of costimulation. Especially in light of the
limited numbers of donors available for pancreatic islet
transplant trials, selection of patients who have a better
prognostic proﬁle would allow for optimal resource
allocation.
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FIG. 1. Individuals with type 1 diabetes are generally diagnosed after a
dramatic reduction in -cell mass. It has been postulated that a person
can lose up to 80% of his or her islet mass prior to showing clinical
evidence of diabetes. The dashed orange line represents 100% mass,
and the solid green line represents the mass required to maintain
insulin independence. The two solid blue lines represent the immune
status of an individual to both auto- and allo-antigens; the slight
posttransplant increase represents the inﬂammatory response to the
islet infusion, followed by decreased reactivity due to immune inter-
vention. A lower pre-transplant immune proﬁle (lower blue line) would
result in a level of immunity that allows for maintenance of insulin
independence, while a higher proﬁle (upper blue line) would be
suppressed but not enough to prevent gradual islet loss due to rejec-
tion and/or recurrent autoimmunity. If immunity is adequately sup-
pressed, the transplanted islet mass can slowly increase over time
(solid orange line).
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